Douglas Fleming

Head of Safety Sciences at BioNTech

Role
Head of Safety Sciences at BioNTech SE
Location
Princeton, NJ, US
LinkedIn followers
500 followers

About Douglas Fleming

Physician and epidemiologist, clinical trialist and expert in Drug Safety. Doug received his BA in humanities and physics from Yale, and served as a Peace Corps Volunteer teacher in Kenya. He earned an MD from Yale Medical School, and did his residency in Internal Medicine at Mount Auburn Hospital of Harvard Medical School. He did his fellowship in Epidemiology with the Epidemic Intelligence Service of the United States Centers for Disease Control (CDC) in Atlanta, Georgia. Doug worked in public health for 15 years, teaching internal medicine at an inner-city health center, and later serving in CDC’s Global AIDS Program in Botswana (southern Africa), running clinical trials for HIV and TB medications. When he returned to the United States in 2007, he joined Bristol-Myers Squibb, where he worked for 5 years on clinical development in diabetes, and he developed epidemiologic tools for safety analyses. He joined Lexicon Pharmaceuticals in 2013 as Medical Lead for telotristat etiprate, and for 3 years led development of this new drug for a particular rare cancer (carcinoid tumor). The drug aims to reduce the severe effects of this tumor on the heart muscle. The drug’s clinical trials were successful, and were published in the Journal of Clinical Oncology. The drug subsequently was approved by FDA and EMA. In 2016, he returned to Bristol-Myers Squibb, where he led a group of physicians and epidemiologists who designed and built advanced epidemiological and clinical tools to detect and understand potential safety signals. In September 2020, he began a new role at BMS as Executive Director, Immunology & Fibrosis & CV, with Medical Capabilities / Medical Data Generation

Experience

  1. Head of Safety Sciences

    BioNTech SE

    Apr 2022 — Present · New York, NY, US

    Collaborates with multiple functions in Safety/PV, Risk Management, Clinical Development, and others to facilitate systematic and thorough assessment of safety for BioNTech medicines in development. To start on the 19th of April, 2022.

Education

  • Harvard Medical School

    Medical Residency, Internal Medicine

    1992 — 1994

  • CDC Epidemic Intelligence Service

    Fellowship in Epidemiology and Public Health

    1995 — 1997

  • Yale University

    BA, Religious Studies and German Literature

    1979 — 1984

  • Yale School of Medicine

    Doctor of Medicine (MD), Medicine

    1987 — 1991

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Douglas Fleming — Head of Safety Sciences at BioNTech SE in Princeton, NJ, US | Unifers